Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074365 | 0.89 | NPC1 (0.67) | RAB9ANPC1LMNAKDM4EALDH1A1 | |
| SCHEMBL4628487 | 0.89 | SMN1; SMN2 (0.52) | RAB9ANPC1LMNAKDM4EEGFR | |
| SCHEMBL4629403 | 0.87 | CRHBP (0.52) | RAB9ANPC1LMNAKDM4EEGFR | |
| SCHEMBL4628721 | 0.85 | RAB9A (0.63) | RAB9ANPC1LMNAKDM4EALDH1A1 | |
| SCHEMBL12218081 | 0.85 | RAB9A (0.76) | SCN5ASCN2ARAB9ANPC1LMNA | |
| SCHEMBL4628517 | 0.82 | SCN5A (0.57) | SCN5ASCN2ARAB9ANPC1LMNA | |
| SCHEMBL4629422 | 0.82 | MEN1 (0.52) | RAB9ANPC1LMNAKDM4EMAPT | |
| SCHEMBL4629228 | 0.81 | NPC1 (0.56) | RAB9ANPC1MAPTSMN1; SMN2TRPV1 | |
| SCHEMBL4629385 | 0.78 | SMN1; SMN2 (0.51) | RAB9ANPC1LMNAALDH1A1MAPT | |
| SCHEMBL23844169 | 0.78 | LMNA (0.76) | RAB9ANPC1LMNAKDM4EEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | claimed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1032556-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1032556-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999020599-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | SCN5A 1196/4885SCN2A 1613/4885RAB9A 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.